Core Insights - Opus Genetics is a clinical-stage biopharmaceutical company focused on developing gene therapies aimed at restoring vision and preventing blindness in patients with inherited retinal diseases (IRDs) [3] Company Overview - The company is developing durable, one-time treatments that target the underlying genetic causes of severe retinal disorders [3] - Opus Genetics has a pipeline that includes seven AAV-based programs, with key candidates being OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration [3] - Additional candidates in development target RHO, CNGB1, RDH12, NMNAT1, and MERTK [3] - The company is also advancing Phentolamine Ophthalmic Solution 0.75%, which is an approved small-molecule therapy for pharmacologically induced mydriasis, with potential applications in presbyopia and low-light visual disturbances following keratorefractive surgery [3] - Opus Genetics is headquartered in Research Triangle Park, NC [3] Upcoming Events - The company will present at several investor conferences, including the Leerink Global Healthcare Conference, Citizens Life Sciences Conference, and RBC Capital Markets Global Ophthalmology Conference [2] - Specific presentation dates and times include March 10, 2026, at 3:00 p.m. ET, March 11, 2026, at 2:50 p.m. ET, and March 25, 2026, at 11:45 a.m. ET [5]
Opus Genetics to Present at Upcoming Investor Conferences in March 2026